Clinical data | |
---|---|
Trade names | Biaxin, others |
Other names | 6-O-Methylerythromycin A |
AHFS/Drugs.com | Monograph |
MedlinePlus | a692005 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Macrolides |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 50% |
Protein binding | Low binding |
Metabolism | Liver |
Elimination half-life | 3–4 h |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.119.644 |
Chemical and physical data | |
Formula | C38H69NO13 |
Molar mass | 747.964 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Clarithromycin, sold under the brand name Biaxin among others, is an antibiotic used to treat various bacterial infections.[3] This includes strep throat, pneumonia, skin infections, H. pylori infection, and Lyme disease, among others.[3] Clarithromycin can be taken by mouth as a tablet or liquid or can be infused intravenously.[3]
Common side effects include nausea, vomiting, headaches, and diarrhea.[3] Severe allergic reactions are rare.[3] Liver problems have been reported.[3] It may cause harm if taken during pregnancy.[3] It is in the macrolide class and works by slowing down bacterial protein synthesis.[3] Clarithromycin resistance is already a major challenge to healthcare systems and such resistance is spreading, leading to recommendations to test the susceptibility of pathogenic organisms to the antibiotic before commencing clarithromycin therapy.[4]
Clarithromycin was developed in 1980 and approved for medical use in 1990.[5][6] It is on the World Health Organization's List of Essential Medicines.[7] Clarithromycin is available as a generic medication.[3] It is made from erythromycin and is chemically known as 6-O-methylerythromycin.[8]